Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …

Checkpoint proteins are an integral part of the immune system and are used by the tumor
cells to evade immune response, which helps them grow uncontrollably. By blocking these …

Over the past two decades, multidisciplinary investigations into the development of
nanoparticles for medical applications have continually increased. However, nanoparticles …

Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains
poorly understood. Recent developments in cancer immunotherapy have demonstrated a …

Cancer immunotherapy is a type of treatment that harnesses the power of the immune
systems of patients to target cancer cells with better precision compared to traditional …

The role of tumor mutational burden (TMB) in shaping tumor immunity is a key question that
has not been addressable using genetically engineered mouse models (GEMMs) of lung …